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Sarcoid Granulomas in 
Malignancy
Komal Arora, Neeraj Kaur and Jae Y. Ro
Abstract
Noncaseating epithelioid granulomas without accompanying systemic symp-
toms of sarcoidosis have been described in association with many primary tumors 
where they are designated as sarcoid-like (SL) reaction. Morphologically, this 
SL reaction is similar to granulomas found in systemic sarcoidosis comprising of 
focal accumulation of epithelioid cells and multinucleated giant cells. They can be 
seen either adjacent to the primary malignancy or in local draining lymph nodes. 
Additionally, sarcoid-like granulomas can affect other organs distant from the 
primary neoplasm, such as the spleen, bone marrow, and skin. This sarcoid-like 
reaction is thought to occur as an immunologic T-cell-mediated response to antigens 
expressed by the neoplastic cells or soluble tumor antigens. Whether the pres-
ence of this sarcoid-like reaction has any prognostic significance in the associated 
neoplasm is unclear.
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1. Introduction
Granulomatous inflammation is a type of chronic tissue reaction characterized 
histologically by accumulation of epithelioid cells and multinucleated giant cells. 
Sarcoidosis is a systemic granulomatous disorder of unknown etiology that affects 
various organs. Sarcoid-like (SL) granulomas/reactions can be seen in patients with 
malignant tumors without the history of systemic sarcoidosis. These reactions were 
first described by Wolbach in 1911 [1]. Subsequently, Herxheimer in 1917 reported 
sarcoidal granulomas in patients with carcinomas of breast, rectum, and cystic 
duct [2]. These granulomas can occur either within the primary tumor, adjacent to 
the primary malignancy, in local draining lymph nodes, or in organs distant from 
the primary malignancy such as the spleen, bone marrow, and skin. This SL reac-
tion is thought to occur in response to antigens expressed by the neoplastic cell or 
soluble tumor antigens that trigger a T-cell-mediated local immune response. Other 
etiologies of granuloma formation in patients with malignancy are co-existing 
sarcoidosis, infectious etiology, and reaction to therapeutic drug or procedure. The 
SL granulomas have been reported to occur with an average frequency of 14% in 
Hodgkin lymphoma cases, 7% in non-Hodgkin lymphomas, 50% in seminomas, less 
than 1% in sarcomas, and 4% in various carcinomas [3, 4].
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2. Histologic features
Morphologically, the granulomas of SL reaction are similar to those seen in 
sarcoidosis. The granulomas are comprised of central focus of epithelioid cells sur-
rounded by a rim of lymphocytes. Both Langhans-type and foreign body-type giant 
cells containing asteroid body and Schaumann body inclusions have been reported 
[5, 6]. Usually, these granulomas are noncaseating with no central necrosis. In 
solid tumors such as renal cell carcinomas, the granulomas have been described in 
intratumoral and peritumoral location as well as in the nonneoplastic kidney and 
draining lymph nodes [7].
3. Pathophysiology
The granuloma formation in sarcoidosis is mediated by T-cells [8]. The 
 granulomas in SL reactions are postulated to be a T-cell-mediated immunologic 
reaction to soluble tumor antigens shed by the tumor cells or released during tumor 
necrosis [3, 9]. In the study by Kurata et al., the authors found that the solitary 
granulomas in SL reactions first occur between lymph sinus and T-zone, the mul-
tiple granulomas mainly occur within T-zone, and the confluent types often occupy 
the whole lymph node except some residual lymphoid follicles [10]. Such a pattern 
suggested that the granulomas grow along the T-zone, where antigen presentation 
mainly occurs. Recently, some authors have also hypothesized that dendritic cells 
play an important role in the mechanism of T-cell activation that leads to formation 
of granulomas [10, 11].
SL reactions have also been reported after interferon therapy in patients with 
malignant melanoma and after interleukin-2 therapy for renal cell carcinoma 
[12, 13].
4. Prognostic significance
A dense lymphocytic infiltrate at the margins of some malignant tumors such 
as medullary carcinoma of the breast and colonic adenocarcinoma has been associ-
ated with an improved prognosis. This improved prognosis has been attributed 
to an immune-mediated cytotoxic T cell response to the tumor. Similarly, the SL 
reactions, which are thought to be an immune response to the tumor antigens, are 
expected to be associated with improved prognosis.
Currently, the prognostic significance of these SL granulomas is debatable. Some 
authors hypothesized that SL granulomatous reactions could play an important role 
in the host’s defense against metastatic spread [9, 14]. Several studies have shown that 
the presence of granulomas in Hodgkin’s disease correlated with improved survival 
in all stages of disease [15–17]. Similarly, SL reactions in gastric carcinoma have been 
reported to have a good prognosis [18]. Takeuchi et al. demonstrated that the incidence 
of SL reactions in the regional lymph nodes decreased as gastric cancer progressed 
[19]. In another study on seven cases of gastric cancer associated with SL reaction, 
none of the patients had any episodes of recurrence, suggesting a more favorable 
prognosis when compared with gastric cancer patients without a SL reaction [20].
SL reactions are relatively less common in solid tumors as compared to lympho-
mas. In a study by Lynch et al., the authors found that SL reaction was associated 
with improved prognosis in small cell carcinoma of the lung [21]. Recently, Steinfort 
et al. [22] studied eight patients with nonsmall cell carcinoma lung where sarcoidal 
granulomas were present in regional lymph nodes. The authors concluded that the 
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presence of sarcoidal reactions within regional lymph nodes of these patients pre-
dicted a lower rate of disease recurrence after definitive surgical resection. However, 
an earlier study by Kamiyoshihara et al. ruled out this hypothesis in lung cancer and 
found the SL reactions to be of no prognostic significance [23]. Similarly Tomimaru 
et al. studied 22 lung carcinoma patients with SL reaction in the regional lymph 
nodes and found no statistically significant difference in the overall survival [24].
Few cases of breast carcinoma and colorectal carcinoma associated with a stro-
mal granulomatous SL reaction have been reported in the literature [25–30]. The 
authors were not able to make a definitive comment on the prognostic significance 
of these SL reactions in these published reports due to limited number of cases.
Recently, we published the largest case series on SL reactions in renal cell 
carcinoma [7]. However, due to the limited follow-up and small number of cases, 
we could not conclude if these SL granulomas had any prognostic significance in 
renal cell carcinomas. We hypothesized that the high content of glycogen and lipid 
in tumor cells of clear cell and clear cell papillary renal cell carcinomas possibly 
triggered a granulomatous reaction, similar to that seen in seminomas.
In a recent case series published by Lashari et al., the authors reported the 
occurrence of granulomatous mediastinal lymphadenitis at a site remote from 
the location of primary gynecological malignancy without evidence of metastatic 
disease [31].
5. Sarcoidosis coexisting with malignancy
Sarcoidosis is associated with an increased risk for cancer development in vari-
ous organs such as lung, liver, or stomach [32, 33]. Many hematologic malignancies 
and melanomas have also been associated with sarcoidosis. Coexistence of sarcoid-
osis and cancer has been associated with a diminished survival rate [34]. Sarcoidosis 
can present in patients before, during, or after diagnosis of malignancy [35, 36].
The association between systemic sarcoidosis and malignant lymphoma was first 
described by Brincker in 1986. The author used the term “Sarcoidosis-lymphoma 
syndrome” to describe this association [37]. It refers to development of lymphoma 
and other hematological malignancies after diagnosis of sarcoidosis as well as 
includes patients with lymphoma and hematological malignancies who subse-
quently develop sarcoidosis [35]. Differentiating between granulomas of systemic 
sarcoidosis and SL granulomas in patients with malignancy is difficult based on 
morphology alone. Diagnosis of systemic sarcoidosis is made in the presence of 
additional well-recognized clinical and radiological findings.
6. Diagnostic dilemmas
Radiologically, a SL reaction can mimic tumor recurrence/deposits in the drain-
ing lymph nodes. Hence, differentiating lymphadenopathy caused by a SL reaction 
and metastatic disease is very important clinically. Definitive diagnosis can be made 
only by histopathological examination of the lymph nodes.
Granulomas in the draining lymph nodes of malignancy can be both infectious 
as well as SL reaction. The center of these granulomas may sometimes have nests or 
isolated tumor cells. Hence, a close scrutiny of such granulomas should be per-
formed to avoid missing metastatic disease. Immunostaining with cytokeratin may 
be required for recognizing these in difficult cases [38].
Knowledge of the usual tumor behavior along with correlating radiologic and 
histologic findings is important to avoid misdiagnosis.
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